Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

综上所述，对神经病理性疼痛的评估和管理需要一个综合的方法，包括全面的临床评估、症状分析和量表评估。随着研究的不断深入，我们相信将会有更多更精确的评估工具出现，帮助医生更好地了解和处理这一复杂的病症。

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Neuropathy, or nerve dysfunction ... adding in an OTC pain med was the perfect pain management trio for me,” she said. Riesebeck was a fan of the Peach flavor she tested: “The flavor was ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...